Published on November 3, 2014

Indian pharma to gain from Latin American countries of Brazil and Mexico, as the recent change in the regulations governing generic drugs may possibly turn them into a pivotal market. According to one of the researched report, the total opportunities of pharma in Latin America pegs USD 60 billion and it also anticipates that the pharma market will rise at 14% to 15% annually.

Moreover the uses of bio-equivalent drugs have been mandated by the governments in countries such as Brazil and Mexico. According to the researched report, almost 2-3% of small shares of the market in the Latin American regions are currently held by the Indian Pharma companies such as Dr Reddy's Laboratories, Lupin, Glenmark Pharmaceuticals and Natco Pharma.

Furthermore by picking up 49% equity in AdwiyaMami SARL Algeria, on 27th October, 2014 one of the Indian pharmaceutical manufacturers Alembic Pharmaceuticals Ltd which is based in Vadodara had announced its access in to the Algerian market. As per the sources, the Algerian drug market has projected approximately USD 3 billion, amid 70% of the market in generics and just about 30% with innovator drugs.

According to the researched analyst, Lupin which is noted as one of the second largest drug producer of India has reported a hike of 54% in the second quarter of 2014 due to robust sales in the United States which is noted as the largest market of the company as well as in its domestic business. In compare to the previous year, the company for the quarter ended 30th September, 2014 had posted a net profit of Rs. 6.3 billion. On the other hand another major drug manufacturer of India Ranbaxy Laboratories also reported a profit of Rs. 4.78 billion, in compare to the loss of last year of Rs. 4.5 billion.